Drugs Industry's Featured Straggler Of The Day: Herbalife Ltd. (HLF)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Herbalife ( HLF) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.2%. By the end of trading, Herbalife fell 90 cents (-2.4%) to $37.38 on light volume. Throughout the day, 3.2 million shares of Herbalife exchanged hands as compared to its average daily volume of six million shares. The stock ranged in price between $37.20-$38.68 after having opened the day at $38.49 as compared to the previous trading day's close of $38.28. Other companies within the Drugs industry that declined today were: Redhill Biopharma ( RDHL), down 11.9%, Immunogen ( IMGN), down 9.7%, MannKind Corporation ( MNKD), down 8.4%, and Rosetta Genomics ( ROSG), down 7.7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Herbalife Ltd., a network marketing company, sells weight management, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products worldwide. Herbalife has a market cap of $3.83 billion and is part of the health care sector. The company has a P/E ratio of 9.2, below the S&P 500 P/E ratio of 17.7. Shares are up 16.2% year to date as of the close of trading on Thursday. Currently there are six analysts that rate Herbalife a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Herbalife as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, impressive record of earnings per share growth, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the positive front, Biocryst Pharmaceuticals ( BCRX), up 13.9%, KYTHERA Biopharmaceuticals ( KYTH), up 9.3%, China Pharma ( CPHI), up 7.1%, and Telik ( TELK), up 6.9%, were all gainers within the drugs industry with Amgen ( AMGN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year

Beleaguered Hedge Fund Titan Bill Ackman Is Having Another Rough Year

With Eyes on Solar Eclipse, Wall Street Stumbles Yet Again